Pim French

Pim French is a Full Professor in the Department of Neurology at Erasmus MC, a leading academic medical center in the Netherlands. His research is highly focused on the molecular and genetic underpinnings of brain tumors, particularly gliomas, astrocytomas, medulloblastomas, and gangliogliomas. He is actively involved in translational neuro-oncology research with an emphasis on DNA methylation profiling, IDH mutations, and tumor microenvironment dynamics.

His research interests span Neuro-Oncology, Molecular Neurobiology, Brain Tumor Genetics, and Neuropathology. He investigates how molecular alterations such as IDH1 mutations and EGFR activation influence tumor behavior and patient outcomes. His work integrates transcriptomics, epigenetics, and clinical data to refine brain tumor classification and guide targeted therapies.

The most recent publications highlight trends in molecular stratification of gliomas, immune evasion mechanisms in IDH-mutant tumors, and transcriptional drivers in medulloblastoma. These studies appear in high-impact journals such as Nature Genetics, Acta Neuropathologica, and Nature Communications, reflecting a strong emphasis on both basic mechanisms and clinical applications in neuro-oncology.

While no specific scientific awards are listed in the provided text, his leadership in developing the updated EANO guidelines for molecular testing in adult gliomas indicates significant professional recognition and influence in the field.

Pim French has supervised research work, as indicated by the 'Supervised Work (6)' notation, suggesting mentorship of junior scientists or students. He is involved in extensive national and international collaborations, particularly in large-scale neuro-oncology research networks. His work contributes to both fundamental understanding and clinical translation in brain tumor management.

He is affiliated with a prominent research group at Erasmus MC focused on neuro-oncology and molecular neuropathology, likely leading or co-leading a research team dedicated to brain tumor genomics and tumor microenvironment studies. This team engages in multi-omics research and participates in global consortia for brain tumor classification and therapy development.